

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Highly Specialised Technology Evaluation

Burosumab for treating X-linked hypophosphataemia [ID1151]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Kyowa Kirin (burosumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Brittle Bone Society • Children Living with Inherited Metabolic Diseases (CLIMB) • Contact a Family • Findacure • Genetic Alliance UK • Muslim Council of Britain • National Children's Bureau • South Asian Health Foundation • Specialised Healthcare Alliance • XLH UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses and Counsellors • British Paediatric and Adolescent Bone Group • British Society for Genetic Medicine • British Society for Paediatric Endocrinology and Diabetes • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • RUDY • Society for Endocrinology • UK Clinical Pharmacy Association • UK Genetic Testing Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Birmingham Children's Hospital NHS Foundation Trust 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS National Services Scotland • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Cystic Fibrosis and Genetic Disorders Group • MRC Clinical Trials Unit • National Institute for Health Research • NIHR Musculoskeletal Biomedical Research Unit, University of Oxford (Nuffield Orthopaedic Centre) • NIHR BioResource for Translational Research in Common and Rare Diseases <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Department of Health • Evelina London Children's Hospital • Great Ormond Street Hospital • Guy's and St Thomas' NHS Foundation Trust • NHS England • Oxford University Hospitals Foundation Trust • Royal Manchester Children's Hospital • Royal Orthopaedic Hospital NHS Trust • University Dental Hospital of Manchester 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the recommendations.

All non-company/sponsor consultees are invited to make an evidence submission or submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the recommendations.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company/sponsor commentators are invited to nominate clinical specialists or patient experts.

¹ Non-companyconsultees are invited to submit statements relevant to the group they are representing.